Bluebird bio nets 3rd gene therapy approval since company split
By Rowan Walrath Somerville’s bluebird bio Inc. has won its third U.S. drug approval since splitting into two companies. On Friday, the Food and Drug Administration approved lovo-cel, a gene therapy for sickle-cell disease. The drug will be marketed under the name Lyfgenia. The FDA announced Lyfgenia’s approval at the same time it said it had approved […]